Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Neurochem ; 74(1): 199-208, 2000 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10617121

RESUMEN

Previous studies indicate that corticotropin-releasing factor (CRF) contributes to the anxiety-like and aversive states associated with drug-induced withdrawal. The present study extends this work by analyzing the CRF receptor subtype involved in withdrawal responses. First, the influence of a selective CRF receptor-1 (CRF-R1) antagonist, CP-154,526, on opiate withdrawal behavior was examined. Pretreatment with the CRF-R1 antagonist significantly attenuated several behavioral signs of naltrexone-induced morphine withdrawal, including writhing, chewing, weight loss, lacrimation, salivation, and irritability, measured during the first hour of withdrawal. Next the expression of CRF-R1 was determined as a second measure of the involvement of this receptor in opiate withdrawal. Naltrexone-induced morphine withdrawal resulted in down-regulation of CRF-R1 mRNA in several brain regions, including the frontal cortex, parietal cortex, striatum, nucleus accumbens, and amygdala, but not in the hypothalamus or periaqueductal gray. Expression of CRF-R2, the other major CRF receptor subtype, was not down-regulated significantly by withdrawal in any of the regions examined, although morphine alone significantly increased levels of this receptor subtype. Taken together, the behavioral and receptor regulation findings indicate that CRF-R1 is the primary mediator of the actions of the CRF system on opiate withdrawal, although it is possible that CRF-R2 contributes to the response.


Asunto(s)
Morfina/efectos adversos , Receptores de Hormona Liberadora de Corticotropina/fisiología , Síndrome de Abstinencia a Sustancias/fisiopatología , Animales , Conducta Animal/efectos de los fármacos , Masculino , Naltrexona/farmacología , Antagonistas de Narcóticos/farmacología , Isoformas de Proteínas/metabolismo , Isoformas de Proteínas/fisiología , Pirimidinas/farmacología , Pirroles/farmacología , Ratas , Ratas Sprague-Dawley , Receptores de Hormona Liberadora de Corticotropina/antagonistas & inhibidores , Receptores de Hormona Liberadora de Corticotropina/metabolismo , Síndrome de Abstinencia a Sustancias/metabolismo , Síndrome de Abstinencia a Sustancias/psicología
2.
J Neurosci ; 19(10): 3674-80, 1999 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-10233999

RESUMEN

The present study demonstrates that the regulator of G-protein-signaling protein type 4 (RGS4) is differentially regulated in the locus coeruleus (LC) and the paraventricular nucleus (PVN) of the hypothalamus by chronic stress and glucocorticoid treatments. Acute or chronic administration of corticosterone to adult rats decreased RGS4 mRNA levels in the PVN but increased these levels in the LC. Similarly, chronic unpredictable stress decreased RGS4 mRNA levels in the PVN but had a strong trend to increase these levels in the LC. Chronic stress also decreased RGS4 mRNA levels in the pituitary. The molecular mechanisms of RGS4 mRNA regulation were further investigated in vitro in the LC-like CATH.a cell line and the neuroendocrine AtT20 cell line using the synthetic corticosterone analog dexamethasone. Consistent with the findings in vivo, dexamethasone treatment caused a dose- and time-dependent decrease in RGS4 mRNA levels in AtT20 cells but a dose- and time-dependent increase in CATH.a cells. RGS4 mRNA regulation seen in these two cell lines seems to be attributable, at least in part, to opposite changes in mRNA stability. The differential regulation of RGS4 expression in the LC and in key relays of the hypothalamic-pituitary-adrenal axis could contribute to the brain's region-specific and long-term adaptations to stress.


Asunto(s)
Encéfalo/fisiología , Glucocorticoides/farmacología , Proteínas del Tejido Nervioso/fisiología , Proteínas/fisiología , Proteínas RGS , Estrés Fisiológico/fisiopatología , Animales , Células Cultivadas , Enfermedad Crónica , Corticosterona/farmacología , AMP Cíclico/fisiología , Dexametasona/farmacología , Retroalimentación , Masculino , Proteínas del Tejido Nervioso/genética , Proteínas/genética , ARN Mensajero/biosíntesis , Ratas , Ratas Sprague-Dawley , Regulación hacia Arriba
3.
Mol Pharmacol ; 54(1): 14-21, 1998 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9658185

RESUMEN

In the current study, we investigated the mechanism by which protein kinase C (PKC) regulates the expression of beta1-adrenergic receptor (beta1AR) mRNA in rat C6 glioma cells. Exposure of the cells to 4beta-phorbol-12-myristate-13-acetate (PMA), an activator PKC, resulted in a down-regulation of both beta1AR binding sites and mRNA levels in a time- and concentration-dependent manner. This effect was not observed with phorbol esters that do not activate PKC and was blocked by bisindolylmaleimide, a specific PKC inhibitor. Activation of PKC did not reduce the half-life of beta1AR mRNA but significantly decreased the activity of the beta1AR promoter, as determined by reporter analysis. A putative response element, with partial homology to a consensus cAMP response element, was identified by mutation analysis of the promoter at positions -343 to -336, relative to the translational start site. Mutation of this putative regulatory element, referred to as a beta1AR-PKC response element, completely blocked the PKC-mediated down-regulation of beta1AR promoter activity. Gel mobility shift analysis detected two specific bands when C6 cell extracts were incubated with a labeled DNA probe containing the beta1AR-PKC response element sequence. Formation of one of these bands was inhibited by an oligonucleotide probe containing a consensus CRE and disrupted by an antibody for cAMP response element binding protein. Based on these studies, we propose that the PKC-induced down-regulation of beta1AR gene transcription in C6 cells is mediated in part by a cAMP response element binding protein-dependent mechanism acting on a novel response element.


Asunto(s)
Carcinógenos/farmacología , Proteína Quinasa C/metabolismo , ARN Mensajero/efectos de los fármacos , Receptores Adrenérgicos beta 1/efectos de los fármacos , Acetato de Tetradecanoilforbol/farmacología , Animales , AMP Cíclico/metabolismo , Regulación hacia Abajo , Glioma/genética , Glioma/metabolismo , Regiones Promotoras Genéticas/efectos de los fármacos , ARN Mensajero/metabolismo , Ratas , Receptores Adrenérgicos beta 1/genética , Células Tumorales Cultivadas/efectos de los fármacos
4.
Mol Pharmacol ; 51(5): 794-9, 1997 May.
Artículo en Inglés | MEDLINE | ID: mdl-9145917

RESUMEN

Corticotropin-releasing factor (CRF) receptors represent one of the primary sites for negative feedback of the pituitary by adrenocortical glucocorticoid hormones; however, the molecular mechanisms involved have yet to be elucidated. The present study examines the mechanisms by which glucocorticoids regulate CRF-R1 expression in the pituitary cell line, AtT-20. Treatment of these cells with dexamethasone resulted in a concentration- and time-dependent inhibition of CRF-R1 mRNA that was significant by 1 hr and maximal after 4 hr. Levels of CRF-R1 mRNA then returned to control levels after 24 hr. Similar changes were observed when the cells were treated with corticosterone. Pro-opiomelanocortin mRNA was also decreased after dexamethasone pretreatment; however, the time course was much slower with a significant effect only detected after 6 hr. Further analysis of the mechanisms that mediate glucocorticoid regulation of CRF-R1 mRNA was conducted These studies demonstrated that glucocorticoid incubation significantly decreases the rate of CRF-R1 gene transcription, as determined by nuclear run-on analysis. In addition, the result demonstrate that glucocorticoid incubation significantly decreases CRF-R1 mRNA stability by approximately 50%. The down-regulation of CRF-R1 mRNA was dependent on de novo protein synthesis, as it was blocked by pretreatment with cycloheximide. This represents a novel mechanism for glucocorticoid negative feedback regulation of CRF-R1 expression.


Asunto(s)
Dexametasona/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Hipófisis/efectos de los fármacos , Receptores de Hormona Liberadora de Corticotropina/efectos de los fármacos , Línea Celular , Hipófisis/citología , Hipófisis/metabolismo , ARN Mensajero/genética , Receptores de Hormona Liberadora de Corticotropina/biosíntesis , Receptores de Hormona Liberadora de Corticotropina/genética , Transcripción Genética
6.
J Neurochem ; 68(1): 362-9, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8978747

RESUMEN

Noradrenergic neuronal networks originating in the locus coeruleus have been implicated in the stress response. In order to study this system in vitro, we have employed a locus coeruleus-like cell line, CATH.a, and have determined the effect of dexamethasone on receptor-mediated second messenger responses. The CATH.a cell line produced increases in intracellular cyclic AMP conversion in response to corticotrophin-releasing factor (EC50 = 6.93 +/- 1.26 nM, maximum conversion = 4.11 +/- 0.20%) and vasoactive intestinal polypeptide (EC50 = 240 +/- 40 nM, maximum conversion = 8.92 +/- 1.24%). Forskolin (10 microM) increased conversion from 0.48 +/- 0.05 to 6.39 +/- 0.38%. The alpha 2-adrenoceptor agonist 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine (UK14304) inhibited the forskolin response with an IC50 of 6.76 +/- 0.11 nM. Carbachol increased total 3H-labelled inositol phosphate accumulation to a maximum of 3.01 +/- 0.79 fold basal (EC50 = 7.94 +/- 0.14 microM). Bradykinin produced a maximum 1.81 +/- 0.05 fold basal stimulation of phosphoinositide hydrolysis (EC50 = 9.12 +/- 0.16 nM). Both carbachol and bradykinin increased intracellular Ca2+ concentration probably via a combination of mobilisation of intracellular stores and gating of extracellular Ca2+. Incubation for 24 h with the glucocorticoid receptor agonist, dexamethasone (1 microM), significantly potentiated the receptor-mediated phosphoinositide responses to all the agents tested; however, of the receptor-mediated increases in cyclic AMP conversion, only the vasoactive intestinal polypeptide response was potentiated. These results show that the CATH.a cell line displays some of the properties expected of locus coeruleus neurons and that glucocorticoid receptor stimulation selectively modulates receptor-mediated increases in second messenger formation.


Asunto(s)
Dexametasona/farmacología , Glucocorticoides/farmacología , Locus Coeruleus/fisiología , Transducción de Señal/efectos de los fármacos , Animales , Calcio/metabolismo , Línea Celular , AMP Cíclico/metabolismo , Locus Coeruleus/citología , Ratones , Fosfatidilinositoles/metabolismo , Receptores de Glucocorticoides/efectos de los fármacos , Receptores de Glucocorticoides/fisiología , Sistemas de Mensajero Secundario
7.
J Neurochem ; 69(5): 1912-9, 1997 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-9349535

RESUMEN

We have previously demonstrated that corticotrophin-releasing factor receptor 1 (CRF-R1) mRNA levels can be down-regulated via activation of the cyclic AMP pathway in CATH.a cells, a neuronal cell line. In this study, we show evidence for down-regulation of CRF-R1 mRNA levels via activation of the protein kinase C (PKC) and calcium second messenger pathways. Incubation of CATH.a cells with phorbol 12-myristate 13-acetate (PMA), an activator of PKC, resulted in a time- and concentration-dependent down-regulation of CRF-R1 mRNA levels. Pretreatment with the inactive phorbol ester 4alpha-phorbol failed to influence significantly CRF-R1 mRNA levels. Incubation with carbachol, a cholinergic agonist known to activate PKC and increase intracellular calcium levels via phosphatidylinositol breakdown, also down-regulated CRF-R1 mRNA levels. Intracellular calcium levels were directly increased using A23187, a calcium ionophore, and thapsigargin, a calcium-ATPase inhibitor. Elevation of intracellular calcium content using either A23187 or thapsigargin significantly down-regulated levels of CRF-R1 mRNA. Furthermore, chelation of calcium with EGTA or blockade of voltage-dependent calcium channels with nifedipine inhibited agonist-mediated down-regulation of CRF-R1 mRNA levels. These results indicate that activation of PKC or calcium signal transduction pathways is sufficient to cause down-regulation of CRF-R1 mRNA levels and that calcium is required for agonist-mediated down-regulation of this receptor.


Asunto(s)
Calcio/metabolismo , Receptores de Hormona Liberadora de Corticotropina/biosíntesis , Acetato de Tetradecanoilforbol/farmacología , Transcripción Genética/efectos de los fármacos , Alcaloides , Animales , Benzofenantridinas , Calcimicina/farmacología , Carbacol/farmacología , Línea Celular , Hormona Liberadora de Corticotropina/farmacología , Regulación hacia Abajo/efectos de los fármacos , Ácido Egtácico/farmacología , Inhibidores Enzimáticos/farmacología , Cinética , Ratones , Nifedipino/farmacología , Fenantridinas/farmacología , Proteína Quinasa C/metabolismo , ARN Mensajero/biosíntesis , Tapsigargina/farmacología
8.
Mol Pharmacol ; 50(5): 1103-10, 1996 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-8913341

RESUMEN

Corticotropin-releasing factor (CRF) is known to play a major role in coordinating neuroendocrine and behavioral responses to stress. We demonstrate that expression of the CRF1 receptor (CRF-R1) is regulated by stress in the brain and by agonist treatments in cultured cells. Expression of CRF-R1 mRNA was decreased in the frontal cortex but increased in the hippocampus by chronic unpredictable stress. Chronic corticosterone administration did not influence levels of CRF-R1 mRNA in either region, suggesting that regulation of CRF-R1 expression is mediated by CRF itself or by another stress-related factor. Differential regulation of CRF-R1 mRNA by agonist treatment was also observed in two cultured cell lines. In CATH.a cells, a neuron-derived cell line, incubation with CRF decreased levels of CRF-R1 mRNA, whereas in AtT-20 cells, a pituitary-derived cell line, agonist (CRF) treatment increased levels of CRF-R1 mRNA. Further studies demonstrated that the observed changes in both cell lines could be accounted for by regulation of CRF-R1 gene transcription and not by altered mRNA stability. Furthermore, agonist-induced down-regulation of CRF-R1 transcription rate in CATH.a cells was found to be dependent on de novo protein synthesis, suggesting the involvement of an inducible repressor. The results show that different cell types show differential transcriptional regulation of the CRF-R1, which could explain the region-specific regulation of receptor expression in the brain.


Asunto(s)
Encéfalo/efectos de los fármacos , Encéfalo/ultraestructura , Receptores de Hormona Liberadora de Corticotropina/agonistas , Receptores de Hormona Liberadora de Corticotropina/fisiología , Estrés Fisiológico/metabolismo , Animales , Encéfalo/metabolismo , Células Cultivadas , Hormona Liberadora de Corticotropina/farmacología , Masculino , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Hormona Liberadora de Corticotropina/biosíntesis , Transcripción Genética
9.
J Neurochem ; 66(4): 1770-3, 1996 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8627337

RESUMEN

We have recently demonstrated that mRNA expression of cyclic AMP (cAMP) response element-binding protein (CREB) is down-regulated in CATH.a cells (a neural-derived cell line) by activation of the cAMP pathway. We now demonstrate that this down-regulation can be accounted for by a decrease in the rate of CREB gene transcription. It was found that cycloheximide, a protein synthesis inhibitor, prevented the forskolin-induced decrease in CREB mRNA levels in CATH.a cells. Nuclear run-on assays demonstrated that forskolin decreased the rate of CREB transcription by close to 50%. Moreover, forskolin decreased chloramphenicol acetyltransferase (CAT) activity in CATH.a cells transiently transfected with a construct containing 1,240 bp of CREB promoter fused to a CAT reporter plasmid. Possible mechanisms by which activation of the cAMP pathway leads to a decrease in CREB gene transcription are discussed.


Asunto(s)
Proteína de Unión a Elemento de Respuesta al AMP Cíclico/genética , Regulación Neoplásica de la Expresión Génica , Animales , Neoplasias Encefálicas , Núcleo Celular/genética , Colforsina/farmacología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/genética , Ratones , Ratones Transgénicos , ARN Mensajero/análisis , Transcripción Genética/efectos de los fármacos , Transcripción Genética/genética , Células Tumorales Cultivadas/fisiología
11.
Br J Pharmacol ; 111(4): 1252-6, 1994 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8032613

RESUMEN

1. The presence of A1 adenosine receptors in CHO-K1 cells transfected with the human brain A1 sequence was confirmed by ligand binding studies using 8-cyclopentyl-[3H] 1,3-dipropylxanthine ([3H]-DPCPX). 2. Alterations in intracellular calcium ([Ca2+]i) were measured with the calcium-sensitive dye, fura-2. 3. N6-cyclopentyladenosine (CPA), the selective A1 agonist, and 5'-N-ethylcarboxaminoadenosine (NECA), a relatively non-selective adenosine receptor agonist, elicited rapid, biphasic increases in [Ca2+]i which involved both mobilisation from intracellular stores and calcium entry. 4. The calcium response to CPA was significantly inhibited by the selective A1 antagonist DPCPX. The non-selective adenosine receptor, xanthine amino congener (XAC), was less potent. 5. The calcium response to CPA was completely prevented by pretreatment of the cells with pertussis toxin implicating the involvement of Gi in the receptor-mediated response. 6. In summary, we present evidence for the coupling of transfected human brain A1 adenosine receptors in CHO-K1 cells to mobilisation of [Ca2+]i via a pertussis toxin-sensitive G protein.


Asunto(s)
Calcio/metabolismo , Toxina del Pertussis , Receptores Purinérgicos P1/fisiología , Factores de Virulencia de Bordetella/farmacología , Adenosina/análogos & derivados , Adenosina/metabolismo , Animales , Encéfalo/fisiología , Células CHO , Cricetinae , Proteínas de Unión al GTP/fisiología , Humanos , Transfección , Xantinas/metabolismo , Xantinas/farmacología
12.
Br J Pharmacol ; 110(4): 1305-10, 1993 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8306069

RESUMEN

1. Increases in intracellular calcium ([Ca2+]i) were measured in chinese hamster cultured ovary cells (clone, CHO-K1), by use of the fluorescent, calcium-sensitive dye, fura-2. 2. Addition of both ATP and UTP elicited rapid increases in [Ca2+]i due to mobilization from intracellular stores and calcium entry across the plasma membrane. 3. Omission of calcium from the extracellular medium and pre-incubation with the inorganic calcium channel blocker, nickel (Ni2+) prevented the calcium entry components of the responses. 4. Investigation of the concentration-response relationships of various analogues of ATP suggests the presence of a purinoceptor which cannot be characterized as P2X or P2Y. In addition, there appears to be a sub-population of P2Y-purinoceptors which do not cross-react with the 'nucleotide' receptor population. 5. Cross-desensitization and additivity experiments suggest that both ATP and UTP activate the same receptor. 6. Pre-incubation with the tumour-promoting agent, beta-phorbol-12,13 dibutyrate (PDBu), caused a reduction in the increases in [Ca2+]i, suggesting a role for protein kinase C in feedback inhibition of purinoceptor responses in this cell line. 7. In summary, we present evidence for the existence of an endogenous P2U-purinoceptor (or 'nucleotide receptor') which is linked to increases in [Ca2+]i in CHO-K1 cells.


Asunto(s)
Calcio/metabolismo , Receptores Purinérgicos P1/fisiología , Adenosina Trifosfato/farmacología , Animales , Células CHO , Cricetinae , Cricetulus , Forbol 12,13-Dibutirato/farmacología , Receptores Purinérgicos P1/efectos de los fármacos , Uridina Trifosfato/farmacología
13.
Biochem Biophys Res Commun ; 195(3): 1294-300, 1993 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-8216261

RESUMEN

The bovine H1-receptor DNA was transfected into Chinese hamster ovary cells (CHO-K1) using an expression vector. Binding studies revealed very high expression levels of the receptor which was found to have a Kd for [3H]-mepyramine of 1 nM. Addition of histamine resulted in a concentration-dependent increase in intracellular calcium which was found to involve both release from intracellular stores and entry across the plasma membrane. Furthermore, the response demonstrated the pharmacological characteristics of an H1-receptor-mediated event. Thus, we present the first report of the high, functional expression of the bovine H1-receptor coupled to mobilisation of intracellular calcium in CHO-K1 cells.


Asunto(s)
Canales de Calcio/fisiología , Calcio/metabolismo , Regulación de la Expresión Génica , Receptores Histamínicos H1/biosíntesis , Animales , Células CHO , Bloqueadores de los Canales de Calcio/farmacología , Bovinos , Cricetinae , Níquel/farmacología , Pirilamina/metabolismo , Receptores Histamínicos H1/genética , Proteínas Recombinantes/biosíntesis , Transfección
14.
Biochem Pharmacol ; 45(3): 611-7, 1993 Feb 09.
Artículo en Inglés | MEDLINE | ID: mdl-8442761

RESUMEN

Addition of angiotensin II (A2; 500 nM) to populations of fura-2-loaded N1E-115 cells resulted in a transient increase in intracellular calcium which was abolished by pre-treatment with the phorbol ester, beta-phorbol-12,13 dibutyrate (PDBu) (1.5 microM). The inhibitory effects were reversed by the protein kinase C inhibitor, staurosporine (150 nM), and down-regulation of protein kinase C was observed over 48 hr. Responses to maximally effective concentrations of histamine (300 microM), ATP (100 microM), UTP (100 microM) and carbachol (100 microM) were similarly inhibited by phorbol pre-treatment but the response to bradykinin (BK) (100 nM) was unaffected. When the concentrations of BK and A2 were adjusted to produce the same-sized calcium signals, PDBu pre-treatment abolished the response to A2 but only partially inhibited the response to BK. From the data presented here we can conclude that the calcium response to BK in N1E-115 cells is less susceptible to the inhibitory effects of protein kinase C activation than the response produced by A2.


Asunto(s)
Angiotensina II/farmacología , Bradiquinina/farmacología , Calcio/metabolismo , Forbol 12,13-Dibutirato/farmacología , Alcaloides/farmacología , Angiotensina II/antagonistas & inhibidores , Animales , Regulación hacia Abajo , Activación Enzimática/efectos de los fármacos , Ratones , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C/metabolismo , Estaurosporina , Células Tumorales Cultivadas/efectos de los fármacos
15.
Biochem Pharmacol ; 45(2): 407-14, 1993 Jan 26.
Artículo en Inglés | MEDLINE | ID: mdl-8094616

RESUMEN

Synaptoneurosomes are a simply derived brain vesicular preparation which are believed to contain elements of both presynaptic and postsynaptic material. Inositol phosphates production and neurotransmitter release in the synaptoneurosome have previously been shown to be under the control of a number of receptor agonists. However, there have been few investigations of the role of intracellular calcium ([Ca2+]i) in these events. In this study we report that potassium (K+; 50 mM) was able to increase [Ca2+]i and subsequently release [3H]noradrenaline in guinea pig cerebral cortical synaptoneurosomes via activation of dihydropyridine-insensitive, voltage-sensitive calcium channels. Veratridine (30 microM) produced similar effects but these involved activation of sodium channels which could be blocked by pre-incubation with tetrodotoxin (0.15 microM). A number of agonists were used to investigate possible modulation of these events and to look for agonist-stimulated mobilization of [Ca2+]i. No evidence was found for either receptor-mediated release of calcium from intracellular stores or for modulation of K(+)-induced neurotransmitter release. This might be related to the observed passive entry of calcium through the synaptoneurosomal membrane and the subsequently high levels of [Ca2+]i.


Asunto(s)
Calcio/metabolismo , Corteza Cerebral/metabolismo , Neurotransmisores/metabolismo , Sinaptosomas/metabolismo , Animales , Calcio/farmacología , Canales de Calcio/efectos de los fármacos , Corteza Cerebral/ultraestructura , Clonidina/farmacología , Fura-2 , Cobayas , Técnicas In Vitro , Isradipino/farmacología , Manganeso/farmacología , Níquel/farmacología , Norepinefrina/metabolismo , Fosfatidilinositoles/metabolismo , Potasio/antagonistas & inhibidores , Potasio/farmacología , Veratridina/farmacología
16.
Br J Pharmacol ; 107(4): 1083-7, 1992 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-1467830

RESUMEN

1. Alterations in the levels of intracellular calcium ([Ca2+]i) and D-myo-inositol-1,4,5-trisphosphate (InsP3) were measured in the murine neuroblastoma cell line clone, N1E-115, by use of the calcium-sensitive dye, fura-2 and a radioreceptor assay, respectively. 2. Exposure of the cells to ATP (100 microM) elicited rapid and transient increases in [Ca2+]i and InsP3, with both responses reaching a maximum between 10-20 s after agonist addition. 3. Investigation of concentration-response data by use of various analogues of ATP suggests the presence of an extracellular receptor which fails to fit into the current classification of purinoceptors. 4. Cross-desensitization experiments suggest that the same receptor can also be activated by the structurally different pyrimidine base, UTP. 5. Application of the tumour-promoting agent, beta-phorbol-12,13 dibutyrate (PDBu) caused a reduction in the increases in both [Ca2+]i and InsP3, suggesting a role for protein kinase C in feedback inhibition of purinoceptor responses in this cell line. 6. In summary, we present the first evidence for the existence of an atypical purinoceptor on a cell line of CNS origin. This receptor is linked to stimulation of phosphoinositide turnover and subsequent mobilisation of intracellular calcium.


Asunto(s)
Adenosina Trifosfato/farmacología , Calcio/metabolismo , Inositol 1,4,5-Trifosfato/metabolismo , Neuronas/metabolismo , Receptores Purinérgicos/fisiología , Animales , Relación Dosis-Respuesta a Droga , Fura-2/metabolismo , Ratones , Neuroblastoma , Neuronas/efectos de los fármacos , Forbol 12,13-Dibutirato/farmacología , Ensayo de Unión Radioligante , Receptores Purinérgicos/efectos de los fármacos , Células Tumorales Cultivadas , Uridina Trifosfato/farmacología
17.
Biochem Pharmacol ; 44(8): 1479-87, 1992 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-1417971

RESUMEN

Addition of ATP (100 microM) to populations of the neuronal cell line N1E-115 caused a transient increase in intracellular calcium ([Ca2+]i) which rapidly reached a peak (maximum of 243 +/- 7 nM above basal) and returned to basal after approximately 50 sec. The response was concentration-dependent (EC50 21 +/- 4 microM) and was unchanged when calcium was omitted from the extracellular medium. Transient increases in D-myo-inositol-1,4,5-trisphosphate levels (InsP3) were also observed over a similar time period. Addition of millimolar ATP, however, produced characteristically different responses; [Ca2+]i again increased rapidly (reaching a maximum of 639 +/- 23 nM above basal) but returned to a new maintained plateau (274 +/- 34 nM) which was abolished by the inorganic calcium channel blocker, nickel (1 mM), and omission of calcium from the extracellular medium. InsP3 levels were also maintained but were, however, unaffected by nickel or removal of extracellular calcium. The qualitative difference in the mechanism of calcium elevation produced with millimolar ATP, compared with lower concentrations, suggests that the N1E-115 cells might also contain a low affinity P2 receptor coupled with a calcium channel.


Asunto(s)
Adenosina Trifosfato/farmacología , Calcio/metabolismo , Inositol 1,4,5-Trifosfato/biosíntesis , Animales , Relación Dosis-Respuesta a Droga , Fura-2 , Manganeso/farmacología , Ratones , Níquel/farmacología , Ésteres del Forbol/farmacología , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismo
18.
Eur J Pharmacol ; 226(2): 163-8, 1992 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-1639111

RESUMEN

The addition of bradykinin to populations of fura-2 loaded N1E-115 neuroblastoma cells produced an increase in intracellular calcium which rapidly reached a peak and returned to baseline within 60 s. The response was concentration dependent and unaffected by removal of extracellular calcium or addition of the inorganic channel blocker Ni2+. Similar transient responses were seen with histamine and angiotensin II and experiments monitoring manganese entry suggest that agonist responses in this cell line involve mainly release of calcium from intracellular stores. However, unlike bradykinin, the response to carbachol, at all concentrations, failed to return completely to baseline suggesting a small secondary influx component and highlighting possible differences between the mechanisms of calcium elevation by these two agonists.


Asunto(s)
Bradiquinina/farmacología , Agonistas de los Canales de Calcio/farmacología , Calcio/metabolismo , Carbacol/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Fura-2 , Humanos , Manganeso/metabolismo , Neoplasias del Sistema Nervioso/metabolismo , Neuroblastoma/metabolismo , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA